Purchase of Shares of 19,000 shares at 27.4
Cambridge Cognition Holdings PLC
23 September 2026
23 September 2026
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Director/PDMR Share Purchases
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company, was informed on 18 September 2026 that, on the same day, Nick Rodgers, Non-Executive Chair of the Company, purchased 19,000 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 27.4 pence per share.
Following this transaction, Nick Rodgers holds an interest in 98,892 Ordinary Shares, representing approximately 0.18% of the Company's issued share capital.
Further information on the purchases is contained in the disclosure tables below.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Nick Rodgers |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Non-Executive Director |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Cambridge Cognition Holdings plc |
||||
|
b) |
LEI |
213800SZKDIN122EPA96 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.01p each
GB00B8DV9647 |
||||
|
b) |
Nature of the transaction |
Purchase of Shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
N/A
|
||||
|
e) |
Date of the transaction |
18 September 2026 |
||||
|
f) |
Place of the transaction |
London Stock Exchange
|
||||
ENQUIRIES
|
Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer
|
Tel: 01223 810700 |
|
Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith Harriet Ward Nigel Birks |
Tel: 020 7220 0500 Corporate Finance Corporate Broking LS Specialist Sales |
|
Singer Capital Markets Limited (Joint Broker) Amber Higgs / Paul Richards / Daniel Ingram |
Tel: 020 7496 3000
|
NOTES TO EDITORS
ABOUT CAMBRIDGE COGNITION
Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care.
The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the CANTAB and Winterlight brands.These assessments are designed to:
- require minimal specialist administration
- deliver objective results in real time or shortly after completion
- reduce administrator bias
- support longitudinal monitoring of cognitive function
Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments.
CANTAB Pathway™is Cambridge Cognition’s latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings:
- CANTAB One– a brief assessment of overall cognitive function
- CANTAB Insight™ – a three-task battery providing deeper insight across five cognitive sub-domains
- CANTAB Plus – specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson’s disease, ADHD, multiple sclerosis, Huntington’s disease, schizophrenia, depression, and Alzheimer’s disease and related dementias
For further information, visit:www.cambridgecognition.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.